Molecular measurement of minimal residual disease in Philadelphia-positive acute lymphoblastic leukaemia

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 1, 2002, Pages 91-103

  Radich, Jerald P ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Acute lymphoblastic leukaemia; Minimal residual disease; Philadelphia chromosome

Indexed keywords

BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMATINIB; PREDNISOLONE; VINCRISTINE; PROTEIN P190; DNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DRUG TARGETING; GENE FUNCTION; GENE STRUCTURE; GENETIC DISORDER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; CELL LINEAGE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE TRANSLOCATION; LEUKEMIA RELAPSE; MOLECULAR GENETICS; MONITORING; PHILADELPHIA CHROMOSOME POSITIVE CELL; REVIEW; ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL; GENETICS;

ANIMALS; DNA, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; NEOPLASM, RESIDUAL; PHILADELPHIA CHROMOSOME;

EID: 0036009610     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0187     Document Type: Article

References (85)

1. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: A report from the Children's Cancer Group
2. Philadelphia positive acute lymphoblastic leukemia in adults: Age distribution, BCR breakpoint and prognostic significance
3. The bcr gene in Philadelphia chromosome positive acute lymphoblastic leukemia
4. bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia
5. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia
6. Unique forms of the abl tyrosine kinase distinguish Phl-positive CML from Phl-positive ALL
7. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity
8. Clonal development and karyotype evolution during leukemogenesis of BCR/ABL transgenic mice
9. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice
10. Heterogeneity of genomic fusion of BCR and ABL in Philadelphia chromosome-positive acute lymphoblastic leukemia
11. Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia
12. Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia
13. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia
14. Chimeric BCR-ABL messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia
15. Molecular diagnosis of the Philadelphia chromosome in chronic myelogenous and acute lymphoblastic leukemias by PCR
16. A novel acute lymphoid leukaemia type BCR/ABL transcript in chronic myelogenous leukaemia
17. A novel 203 kD aberrant BCR-ABL product in a girl with Philadelphia chromosome positive acute lymphoblastic leukaemia
18. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia
19. Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis
20. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation
21. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia
22. New insights into the biology of Philadelphia-chromosome-positive acute lymphoblastic leukaemia using a combination of May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level
23. + acute lymphoblastic leukemia
24. Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: Determination by analysis of individual colonies with the polymerase chain reaction
25. Variable Philadelphia breakpoints and potential lineage restriction of bcr rearrangement in acute lymphoblastic leukemia
26. Prognostic implications of breakpoint and lineage heterogeneity in Philadelphia-positive acute lymphoblastic leukemia: A review
27. First intron and M-bcr breakpoints are restricted to the lymphoid lineage in Philadelphia positive acute lymphoblastic leukemia
28. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia
29. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
30. A Pediatric Oncology Group study. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Clinical and cytogenetic characteristics and treatment outcome
31. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: Durable responses to chemotherapy associated with low initial white blood cell counts
32. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 ALL-BFM-90 and CoALL-05-92
33. +) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome
34. Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy
35. MRC Adult Leukaemia Working Party. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA
36. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B Study Blood (8762)
37. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and leukemia group B study 8811
38. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
39. Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia
40. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia
41. Adult Philadelphia-chromosome-positive acute lymphoblastic leukemia: Experience of treatments during a ten-year period
42. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: Correlations with hematologic findings outcome
43. Prospective karyotype analysis in adult acute lymphoblastic leukemia: The cancer and leukemia Group B experience
44. Philadelphia-chromosome-positive adult acute lymphocytic leukemia: Characteristics, treatment results, and prognosis in 41 patients
45. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
46. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
47. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
48. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission
49. Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia
50. Detection and significance of bcr-abl mRNA transcripts and fusion proteins in Philadelphia-positive adult acute lymphoblastic leukemia
51. Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction
52. A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias
53. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro
54. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia
55. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia
56. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
57. Polymerase chain reaction-based detection of minimal residual disease in acute lymphoblastic leukemia predicts relapse after allogeneic BMT
58. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia
59. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction
60. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation
61. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia
62. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR
63. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using an in situ RT-PCR assay
64. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics
65. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: Possible eradication of minimal residual disease by marrow transplantation
66. PCR-monitoring of minimal residual leukaemia after conventional chemotherapy and bone marrow transplantation in BCR-ABL-positive acute lymphoblastic leukaemia
67. Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoplastic leukaemia using quantitative competitive polymerase chain reaction
68. Good correlation between RT-PCR analysis and relapse in Philadelphia (Phl)-positive acute lymphoblastic leukemia (ALL)
69. Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive leukemia
70. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: Comparison of blood and bone marrow
71. The use of PCR technology for detecting minimal residual disease in patients with leukemia
72. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
73. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells
74. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia
75. Kinetic selectivity of complementary nucleic acids: Bcr-abl-directed antisense RNA and ribozymes
76. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide
77. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides
78. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene
79. BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism
80. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
81. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: Abrogative effect on the transformation of murine hematopoietic cells by transfection of a oncoprotein P210bcr/abl and preferential inhibition on Phl-positive leukemia cell growth
82. r 190 000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
83. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
84. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
85. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification